In addition, our study proved that synergistic inhibition of PRC1 and PRC2 can bring higher sensitivity to oxaliplatin, and similar therapeutic strategies have recently been reported in glioblastomas treatment where the investigators successfully used molecular inhibitors of BMI1 and EZH2 to control proneural and mesenchymal tumors under the limits of detection [46]. This evidence concerns the gene BMI1 and mesenchymal cell neoplasm.